Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Combinations of long-acting bronchodilators are recommended to reduce the rate of chronic obstructive pulmonary disease (COPD) exacerbations. It is unclear whether combining olodaterol, a long-acting beta-agonist, with tiotropium, a long-acting anti-muscarinic, reduces the rate of exacerbations compared with tiotropium alone.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet Respir Med

Title: The Lancet. Respiratory medicine

Publisher: Elsevier BV

ISSN (Electronic): 2213-2619

ISSN (Print): 2213-2600

Publication date (Electronic): May 2018

Volume: 6

Issue: 5

Affiliations

[1 ] Clinical Science Centre, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK. Electronic address: pmacal@liverpool.ac.uk.

[2 ] Department of Pulmonary Medicine and Critical Care, University of Texas Health Sciences Center and South Texas Veterans' Health Care System, San Antonio, TX, USA.

[3 ] Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, USA.

[4 ] Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.

[5 ] The George Institute of Global Health Sydney, Concord Clinical School, The University of Sydney, UNSW, Sydney, NSW, Australia.

[6 ] Clinical Respiratory Science Division, National Heart and Lung Institute, Imperial College London, London, UK.

[7 ] LungClinic Grosshansdorf, Grosshansdorf, Germany.

Article

Publisher Item ID: S2213-2600(18)30102-4

DOI: 10.1016/S2213-2600(18)30102-4

PubMed ID: 29605624

SO-VID: 0f8ffa1a-212f-4af9-854d-a4bf045934a4

History

Data availability:

Comments

Comment on this article

scite_

Cited by 80

See all cited by

- Version 1